Zyla Life Sciences (fka ZCOR)

[realfast95]

Egalet Announces ARYMO ER Added to Large Payer Medicare Part D Formulary

WAYNE, Pa., Nov. 6, 2017 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced that a large payer will provide coverage of ARYMO® ER (morphine sulfate) extended-release tablets for oral use –CII for its Medicare Part D members.

"Providing access to ARYMO ER for Medicare patients is important given the high incidence of chronic pain in this population as well as the familiarity and utilization of extended-release (ER) morphine," said Patrick Shea, chief commercial officer of Egalet. "Formulary coverage within this particular payer's Medicare Part D population comes sooner than we had expected, and is a promising development at this stage of our commercial launch of our abuse-deterrent, ER morphine, ARYMO ER."

The new formulary drug coverage for approximately 1.4 mm lives takes effective immediately and includes all Egalet brands.